Use of Cannabidiol in the Management of Insomnia: A Systematic Review
- PMID: 36149724
- DOI: 10.1089/can.2022.0122
Use of Cannabidiol in the Management of Insomnia: A Systematic Review
Abstract
Background: Cannabidiol (CBD), one of the major cannabinoids derived from the cannabis plant, is available over the counter. CBD is often used by patients for the management of insomnia, yet research supporting CBDs effectiveness as a treatment for insomnia is inadequate. Objective: The objective of this review was to critically evaluate the literature regarding the therapeutic benefits of CBD in the management of insomnia. Methods: A comprehensive search of the following databases from inception to December 29, 2021, was conducted: Ovid MEDLINE® and Epub Ahead of Print, In-Process & Other Non-Indexed Citations and Daily, Ovid Embase, Ovid Cochrane Central Register of Controlled Trials, Ovid Cochrane Database of Systematic Reviews, and Scopus. The search included randomized controlled trials, nonrandomized experimental studies, cross-sectional studies, cohort studies, case series, and case reports. Risk of bias was assessed with the Agency for Healthcare Research and Quality design-specific recommended criteria. Results: Thirty-four studies were eligible for inclusion. All studies reported improvement in the insomnia symptoms of at least a portion of their participants. Of the 34 studies, 19 studies used CBD predominant therapy and 21 studies used nearly equal ratios of CBD to Δ9-tetrahydrocannabinol (THC). Of the studies that performed hypothesis testing, 4 of 7 studies with a CBD predominant arm and 12 of 16 studies with a nearly equal ratio of CBD to THC arm reported significant improvement in insomnia outcomes. However, only 2 of the 34 studies focused on patients with insomnia, of which 1 study was a case report. Additionally, several studies used nonvalidated subjective measures, and most studies failed to include objective measures for symptom assessment. Conclusions: The results of our systematic review suggest that CBD alone or with equal quantities of THC may be beneficial in alleviating the symptoms of insomnia. Nevertheless, future research assessing CBDs effectiveness in population of patients specifically with insomnia utilizing validated subjective and objective measures is necessary before definitive inferences can be made.
Keywords: cannabidiol; cannabinoids; insomnia; sleep.
Similar articles
-
Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.Cochrane Database Syst Rev. 2022 Feb 1;2(2022):CD014217. doi: 10.1002/14651858.CD014217. Cochrane Database Syst Rev. 2022. PMID: 36321557 Free PMC article.
-
Changes in delta-9-tetrahydrocannabinol (THC) and cannabidiol (CBD) concentrations in cannabis over time: systematic review and meta-analysis.Addiction. 2021 May;116(5):1000-1010. doi: 10.1111/add.15253. Epub 2020 Nov 7. Addiction. 2021. PMID: 33160291 Review.
-
Cannabidiol (CBD) and Δ9-tetrahydrocannabinol (THC) for chronic insomnia disorder ('CANSLEEP' trial): protocol for a randomised, placebo-controlled, double-blinded, proof-of-concept trial.BMJ Open. 2020 May 18;10(5):e034421. doi: 10.1136/bmjopen-2019-034421. BMJ Open. 2020. PMID: 32430450 Free PMC article.
-
Living Systematic Review on Cannabis and Other Plant-Based Treatments for Chronic Pain: 2022 Update [Internet].Rockville (MD): Agency for Healthcare Research and Quality (US); 2022 Sep. Report No.: 22-EHC042. Rockville (MD): Agency for Healthcare Research and Quality (US); 2022 Sep. Report No.: 22-EHC042. PMID: 36351096 Free Books & Documents. Review.
-
A randomised controlled trial of vaporised Δ9-tetrahydrocannabinol and cannabidiol alone and in combination in frequent and infrequent cannabis users: acute intoxication effects.Eur Arch Psychiatry Clin Neurosci. 2019 Feb;269(1):17-35. doi: 10.1007/s00406-019-00978-2. Epub 2019 Jan 19. Eur Arch Psychiatry Clin Neurosci. 2019. PMID: 30661105 Clinical Trial.
Cited by
-
Limited Impact of Cannabidiol on Health-related Quality of Life of People With Long-term Controlled HIV: A Double-blind, Randomized, Controlled Trial.Open Forum Infect Dis. 2024 Aug 27;11(9):ofae492. doi: 10.1093/ofid/ofae492. eCollection 2024 Sep. Open Forum Infect Dis. 2024. PMID: 39296339 Free PMC article. Clinical Trial.
-
The Effect of Cannabidiol on Performance and Post-Load Recovery among Healthy and Physically Active Individuals: A Systematic Review.Nutrients. 2024 Aug 24;16(17):2840. doi: 10.3390/nu16172840. Nutrients. 2024. PMID: 39275158 Free PMC article. Review.
-
The effect of nightly use of 150 mg cannabidiol on daytime neurocognitive performance in primary insomnia: a randomized controlled pilot trial.Psychopharmacology (Berl). 2024 Aug 17. doi: 10.1007/s00213-024-06674-x. Online ahead of print. Psychopharmacology (Berl). 2024. PMID: 39153080
-
The Development of Cannabinoids as Therapeutic Agents in the United States.Pharmacol Rev. 2024 Aug 15;76(5):915-955. doi: 10.1124/pharmrev.123.001121. Pharmacol Rev. 2024. PMID: 38849155 Review.
-
Sleep, Glial Function, and the Endocannabinoid System: Implications for Neuroinflammation and Sleep Disorders.Int J Mol Sci. 2024 Mar 9;25(6):3160. doi: 10.3390/ijms25063160. Int J Mol Sci. 2024. PMID: 38542134 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical